The activation of FOXO3 in such glycolytic tumors, either via genotoxic drug treatment or due to hypoxia may provide a significant growth advantage leading to stage IV cancer cells that resist cancer therapy as demonstrated in Figure 1. Here, FOXO3 is linked to cancer.